Cell-based therapies for diabetic complications

Paola Secchiero, Stella Bernardi, Giovanni Maria Severini, Giorgio Zauli

Research output: Contribution to journalArticle

Abstract

In recent years, accumulating experimental evidence supports the notion that diabetic patients may greatly benefit from cell-based therapies, which include the use of adult stem and/or progenitor cells. In particular, mesenchymal stem cells and the circulating pool of endothelial progenitor cells have so far been the most studied populations of cells proposed for the treatment of vascular complications affecting diabetic patients. We review the evidence supporting their use in this setting, the therapeutic benefits that these cells have shown so far as well as the challenges that cell-based therapies in diabetic complications put out.

Original languageEnglish
Article number872504
JournalExperimental Diabetes Research
Volume2012
DOIs
Publication statusPublished - 2012

Fingerprint

Diabetes Complications
Cell- and Tissue-Based Therapy
Diabetic Angiopathies
Adult Stem Cells
Mesenchymal Stromal Cells
Stem Cells
Therapeutics
Population
Therapy
Complications
Cells
Endothelial Progenitor Cells

ASJC Scopus subject areas

  • Medicine(all)
  • Endocrinology, Diabetes and Metabolism
  • Music

Cite this

Cell-based therapies for diabetic complications. / Secchiero, Paola; Bernardi, Stella; Severini, Giovanni Maria; Zauli, Giorgio.

In: Experimental Diabetes Research, Vol. 2012, 872504, 2012.

Research output: Contribution to journalArticle

Secchiero, Paola ; Bernardi, Stella ; Severini, Giovanni Maria ; Zauli, Giorgio. / Cell-based therapies for diabetic complications. In: Experimental Diabetes Research. 2012 ; Vol. 2012.
@article{f44ee20be4e94d6d85426d66dbbae757,
title = "Cell-based therapies for diabetic complications",
abstract = "In recent years, accumulating experimental evidence supports the notion that diabetic patients may greatly benefit from cell-based therapies, which include the use of adult stem and/or progenitor cells. In particular, mesenchymal stem cells and the circulating pool of endothelial progenitor cells have so far been the most studied populations of cells proposed for the treatment of vascular complications affecting diabetic patients. We review the evidence supporting their use in this setting, the therapeutic benefits that these cells have shown so far as well as the challenges that cell-based therapies in diabetic complications put out.",
author = "Paola Secchiero and Stella Bernardi and Severini, {Giovanni Maria} and Giorgio Zauli",
year = "2012",
doi = "10.1155/2012/872504",
language = "English",
volume = "2012",
journal = "Experimental Diabesity Research",
issn = "1543-8600",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Cell-based therapies for diabetic complications

AU - Secchiero, Paola

AU - Bernardi, Stella

AU - Severini, Giovanni Maria

AU - Zauli, Giorgio

PY - 2012

Y1 - 2012

N2 - In recent years, accumulating experimental evidence supports the notion that diabetic patients may greatly benefit from cell-based therapies, which include the use of adult stem and/or progenitor cells. In particular, mesenchymal stem cells and the circulating pool of endothelial progenitor cells have so far been the most studied populations of cells proposed for the treatment of vascular complications affecting diabetic patients. We review the evidence supporting their use in this setting, the therapeutic benefits that these cells have shown so far as well as the challenges that cell-based therapies in diabetic complications put out.

AB - In recent years, accumulating experimental evidence supports the notion that diabetic patients may greatly benefit from cell-based therapies, which include the use of adult stem and/or progenitor cells. In particular, mesenchymal stem cells and the circulating pool of endothelial progenitor cells have so far been the most studied populations of cells proposed for the treatment of vascular complications affecting diabetic patients. We review the evidence supporting their use in this setting, the therapeutic benefits that these cells have shown so far as well as the challenges that cell-based therapies in diabetic complications put out.

UR - http://www.scopus.com/inward/record.url?scp=84926231717&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926231717&partnerID=8YFLogxK

U2 - 10.1155/2012/872504

DO - 10.1155/2012/872504

M3 - Article

AN - SCOPUS:84926231717

VL - 2012

JO - Experimental Diabesity Research

JF - Experimental Diabesity Research

SN - 1543-8600

M1 - 872504

ER -